Dr. Ira-Ida Skvortsova studied medicine at the Altai State Medical University (Russia) from 1981-1987. She completed her oncology residency at the same University, as well as an ESMO research fellowship at Innsbruck Medical University (Austria). Since 2000, Dr. Skvortsova is a head of the Laboratory for Translational Research in Radiation Oncology (Dept. of Therapeutic Radiology and Oncology, Innsbruck Medical University).
Dr. Ira-Ida Skvortsova research interests include Mechanisms of the primary and secondary resistance to anti-cancer treatment approaches (chemotherapy, targeted therapeutics, radiation therapy), Signal transduction pathways involved in carcinogenesis and anti-cancer response, Cancer stem cells and their role in local and distant tumor recurrences after treatment, Proteome approach in biomarker development.
1. How many years have you been associated with the current research?
2. What is the research topic you are working on now?
Treatment of cancer: therapy resistance, molecular mechanisms, cancer stem cells, proteomics
3. What are attributes for a quality article?
Novel data and high quality research methods
4. Do you have any research funding (NIH or other national funding) now?
Yes, various Austrian Foundations
5. When did you become an editor of OMICS Journal?
6. Where can the journal find the maximum scope in terms of niche?
Information about new issues of the journal should be widely distributed among basic and clinical cancer researchers. Potential authors should be permanently invited to submit their articles (better if they would be free of charge at least for young researchers).
7. What is your greatest career accomplishment?
Award from Austrian Radiation Oncology Society for outstanding achievements in radiation oncology research
8. How does the published scientific content assist the potential researchers?
Researchers should at least receive information about journal’s content. European researchers have limited information about the journal and published articles.
9. What is the purpose of serving as an editor?
To be familiarized with the novel data in cancer research. Additionally, this is an honor for researchers to serve as an editor.
10. Do you have any patents?
11. Have you contributed any editorials or papers (any types) to OMICS Journals in the past two years?
12. Do you plan to contribute any editorials or papers to OMICS Journals in the next year?
I do not know yet. Perhaps yes
13. How would you define your experience with OMICS Group?
OMICS Group should more actively contact with European researchers
14. Your opinion on conducting Editorial Board meetings at related Conferences?
I find that this is a very good idea. However, again I would like to note that OMICS group should be presented at European Congresses as well. European Editorial Board members could also have their meetings during conferences. Furthermore, Editorial Board members could also distribute information about their colleagues and OMICS group should help us to do it (to provide flyers, information about upcoming issues, invite potential authors, etc.) For example, I am a member of a number of European Cancer Societies, regularly we have meetings (annual meetings of the small groups (EORTC), congresses and symposiums of international and national societies), hence I could always bring and distribute information during meetings and congresses. Unfortunately, I was never asked by the OMICS group to do it.
15. Would you recommend OMICS to your friends or colleagues?
Yes and I have already done it.
16. How do you differentiate Journal of Gastrointestinal & Digestive System with other journals in the field?
Of course, all researchers would like to publish their articles in the journals that are abstracted/indexed in Medline/PubMed, Scopus, etc. Since the Journal of Gastrointestinal & Digestive System has not been indexed in these systems, it loses researchers and potential authors.